Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05548205
NA

Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge

Sponsor: NYU Langone Health

View on ClinicalTrials.gov

Summary

The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2024-12-16

Completion Date

2027-04-30

Last Updated

2025-10-02

Healthy Volunteers

No

Conditions

Interventions

DEVICE

Continuous Glucose Monitor

Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.

DEVICE

Blood Glucose Monitor

Self-administered according to investigator instruction.

Locations (1)

NYU Langone Hospital - Long Island

Mineola, New York, United States